Denali Therapeutics Company Top Insiders
DNLI Stock | USD 21.93 0.26 1.20% |
Denali Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Denali Therapeutics suggests that almost all insiders are panicking. Denali Therapeutics employs about 390 people. The company is managed by 16 executives with a total tenure of roughly 26 years, averaging almost 1.0 years of service per executive, having 24.38 employees per reported executive.
Ryan Watts CEO President CEO, Co-Founder, Director |
Denali Therapeutics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2025-01-07 | Steve E Krognes | Disposed 3339 @ 20.81 | View | ||
2025-01-06 | Ryan J Watts | Disposed 29266 @ 20.22 | View | ||
2025-01-02 | Vicki L Sato | Disposed 3080 @ 20.91 | View | ||
2024-11-07 | Vicki L Sato | Disposed 1020 @ 30 | View | ||
2024-10-18 | Ryan J Watts | Disposed 40000 @ 27.69 | View | ||
2024-09-30 | Steve E Krognes | Disposed 30000 @ 29.03 | View | ||
2024-07-01 | Steve E Krognes | Disposed 30000 @ 22.12 | View | ||
2024-06-13 | Steve E Krognes | Disposed 688 @ 21.79 | View | ||
2024-06-06 | Jennifer E Cook | Disposed 1458 @ 21.73 | View | ||
2024-04-15 | Vicki L Sato | Disposed 1666 @ 18.29 | View | ||
2024-04-01 | Steve E Krognes | Disposed 92500 @ 20.5 | View | ||
2024-02-15 | Vicki L Sato | Disposed 1666 @ 18.37 | View | ||
2024-02-13 | Steve E Krognes | Disposed 2750 @ 17.29 | View | ||
2024-01-16 | Vicki L Sato | Disposed 1666 @ 18.42 | View |
Monitoring Denali Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Denali |
Denali Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Denali Therapeutics' future performance. Based on our forecasts, it is anticipated that Denali will maintain a workforce of under 390 employees by February 2025.Denali Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2381) % which means that it has lost $0.2381 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3509) %, meaning that it created substantial loss on money invested by shareholders. Denali Therapeutics' management efficiency ratios could be used to measure how well Denali Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.12. The current Return On Capital Employed is estimated to decrease to -0.17. As of now, Denali Therapeutics' Asset Turnover is increasing as compared to previous years.The current Common Stock Shares Outstanding is estimated to decrease to about 86.7 M. The Denali Therapeutics' current Net Loss is estimated to increase to about (278.7 M)
Denali Therapeutics Workforce Comparison
Denali Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 18,534. Denali Therapeutics holds roughly 390 in number of employees claiming about 2.1% of equities under Health Care industry.
Denali Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Denali Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Denali Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Denali Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-03-01 | 0.75 | 6 | 8 | 650,160 | 73,659 |
2024-12-01 | 0.4 | 6 | 15 | 147,792 | 296,891 |
2024-06-01 | 3.6 | 18 | 5 | 214,812 | 97,986 |
2024-03-01 | 0.4118 | 7 | 17 | 837,840 | 187,491 |
2023-09-01 | 0.1053 | 2 | 19 | 12,526 | 64,730 |
2023-06-01 | 1.8571 | 26 | 14 | 263,650 | 186,564 |
2023-03-01 | 0.3571 | 10 | 28 | 742,920 | 201,843 |
2022-12-01 | 0.25 | 1 | 4 | 20,000 | 60,000 |
2022-09-01 | 0.25 | 3 | 12 | 107,500 | 181,656 |
2022-06-01 | 5.6667 | 17 | 3 | 233,465 | 60,000 |
2022-03-01 | 0.7647 | 13 | 17 | 719,352 | 139,903 |
2021-12-01 | 0.0323 | 1 | 31 | 100,000 | 452,938 |
2021-09-01 | 0.0303 | 1 | 33 | 9,045 | 114,936 |
2021-06-01 | 0.5778 | 26 | 45 | 182,801 | 898,272 |
2021-03-01 | 0.1429 | 16 | 112 | 639,650 | 3,290,321 |
2020-12-01 | 0.1333 | 2 | 15 | 52,906 | 633,847 |
2020-09-01 | 0.8889 | 8 | 9 | 102,572 | 1,471,681 |
2020-06-01 | 1.0667 | 16 | 15 | 147,488 | 2,867,855 |
2020-03-01 | 1.3 | 13 | 10 | 975,687 | 3,930,919 |
2019-12-01 | 0.1765 | 3 | 17 | 8,961 | 103,104 |
2019-09-01 | 0.2857 | 6 | 21 | 25,470 | 897,140 |
2019-06-01 | 0.3103 | 18 | 58 | 260,178 | 289,747 |
2019-03-01 | 0.3387 | 21 | 62 | 845,781 | 368,991 |
2018-12-01 | 0.3 | 6 | 20 | 104,322 | 209,278 |
2018-09-01 | 0.75 | 3 | 4 | 33,858 | 71,667 |
2018-06-01 | 7.0 | 7 | 1 | 172,898 | 5,918 |
2018-03-01 | 5.0 | 5 | 1 | 877,954 | 0.00 |
2017-12-01 | 0.9474 | 54 | 57 | 58,151,022 | 55,573,197 |
Denali Therapeutics Notable Stakeholders
A Denali Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Denali Therapeutics often face trade-offs trying to please all of them. Denali Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Denali Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Ryan Watts | President CEO, Co-Founder, Director | Profile | |
Dana Andersen | CTO and Manufacturing Officer | Profile | |
Steve Krognes | Treasurer Director | Profile | |
Peter Chin | Senior Affairs | Profile | |
Carole MD | Chief Development | Profile | |
Mark Rowen | Vice Development | Profile | |
Chris Walsh | General Counsel | Profile | |
Tyler Nielsen | Senior Finance | Profile | |
Cindy Dunkle | Chief Officer | Profile | |
Joe Lewcock | Chief Officer | Profile | |
Laura Hansen | Vice Relations | Profile | |
Chris JD | General Counsel | Profile | |
Alexander MD | CFO, CoFounder | Profile | |
Marc TessierLavigne | Chairman CoFounder | Profile | |
Tony Estrada | Senior Sciences | Profile | |
Katie Peng | Chief Officer | Profile |
About Denali Therapeutics Management Performance
The success or failure of an entity such as Denali Therapeutics often depends on how effective the management is. Denali Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Denali management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Denali management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.11) | (0.12) | |
Return On Capital Employed | (0.16) | (0.17) | |
Return On Assets | (0.11) | (0.12) | |
Return On Equity | (0.16) | (0.17) |
Denali Therapeutics Workforce Analysis
Traditionally, organizations such as Denali Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Denali Therapeutics within its industry.Denali Therapeutics Manpower Efficiency
Return on Denali Therapeutics Manpower
Revenue Per Employee | 847.5K | |
Revenue Per Executive | 20.7M | |
Net Loss Per Employee | 372.4K | |
Net Loss Per Executive | 9.1M | |
Working Capital Per Employee | 2.5M | |
Working Capital Per Executive | 61.6M |
Complementary Tools for Denali Stock analysis
When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
CEOs Directory Screen CEOs from public companies around the world | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |